January 07, 2026-- NeuraLight, the leader in developing precision biomarkers for neurology, today announced the completion of PALOMA, a pioneering study comparing eye-movement measures with standard ...
PALOMA study is one of the largest longitudinal studies using eye-movement biomarkers in patients with Parkinson’s diseaseNEW YORK & TEL AVIV, Israel--(BUSINESS WIRE)--NeuraLight, the leader in ...
Jesy Nelson noticed worrying signs about her twin daughters’ Ocean Jade and Story Monroe’s health, weeks before they were ...
A growing body of research suggests that some dreams might indicate the existence of physiologic changes before conventional ...
Clinical outcomes from routine practice confirm ocrelizumab effectiveness in relapsing MS, with low rates of disability worsening over 4 years.
Changes in motor units closely reflect disease severity in people with spinal muscular atrophy (SMA), suggesting potential ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback